Pathogenesis of NASH: the Impact of Multiple Pathways
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Purpose of reviewAdvancing our understanding of the mechanisms that underlie NASH pathogenesis.Recent findingsRecent findings on NASH pathogenesis have expanded our understanding of its complexity including (1) there are multiple parallel hits that lead to NASH; (2) the microbiota play an important role in pathogenesis, with bacterial species recently shown to accurately differentiate between NAFL and NASH patients; (3) the main drivers of liver cell injury are lipotoxicity caused by free fatty acids (FFAs) and their derivatives combined with mitochondrial dysfunction; (4) decreased endoplasmic reticulum (ER) efficiency with increased demand for protein synthesis/folding/repair results in ER stress, protracted unfolded protein response, and apoptosis; (5) upregulated proteins involved in multiple pathways including JNK, CHOP, PERK, BH3-only proteins, and caspases result in mitochondrial dysfunction and apoptosis; and (6) subtypes of NASH in which these pathophysiological pathways vary may require patient subtype identification to choose effective therapy.SummaryRecent pathogenesis studies may lead to important therapeutic advances, already seen in patients treated with ACC, ASK1 and SCD1 inhibitors, and FXR agonists. Further, advancing our understanding of mechanisms underlying NASH pathogenesis and the complex interplay between them will be crucial for developing effective therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
Mediators of endoplasmic reticulum stress-induced apoptosis
Szegezdi, E., Logue, S. E., Gorman, A. M., & Samali, A. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400779 · Cited by 2,345
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citationZhu, L., Baker, S. S., Gill, C., Liu, W., Alkhouri, R., Baker, R. D., & Gill, S. R. (2013) · Hepatology · doi:10.1002/hep.26093 · Cited by 1,708
The endoplasmic reticulum: structure, function and response to cellular signaling
Schwarz, D. S., & Blower, M. D. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2052-6 · Cited by 1,613
Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo‐Perez, F., Guy, C. D., Seed, P. C., Rawls, J. F., David, L. A., et al. (2016) · Hepatology · doi:10.1002/hep.28356 · Cited by 1,483
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Self-citationLiver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295
Leptin-Replacement Therapy for Lipodystrophy
Oral, E. A., Simha, V., Ruiz, E., Andewelt, A., Premkumar, A., Snell, P., Wagner, A. J., DePaoli, A. M., Reitman, M. L., Taylor, S. I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012437 · Cited by 1,247
Cited by
The ménage à trois of autophagy, lipid droplets and liver disease
Filali-Mouncef, Y., Hunter, C., Roccio, F., Zagkou, S., Dupont, N., Primard, C., Proikas-Cezanne, T., & Reggiori, F. (2022) · Autophagy · doi:10.1080/15548627.2021.1895658 · Cited by 361
Therapeutic pipeline in nonalcoholic steatohepatitis
Vuppalanchi, R., Noureddin, M., Alkhouri, N., & Sanyal, A. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00408-y · Cited by 278
Self-citationReview of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis
Al Attar, A., Antaramian, A., & Noureddin, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1894127 · Cited by 47
“growth factor beta-dependent pathway (TGF-B) (Figure 1)[25].”
Self-citationHernández, A., Reyes, D., Geng, Y., Arab, J. P., Cabrera, D., Sepulveda, R., Solis, N., Buist-Homan, M., Arrese, M., & Moshage, H. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165857 · Cited by 42
St. Rose, K., Yan, J., Xu, F., Williams, J., Dweck, V., Saxena, D., Schwabe, R. F., & Caviglia, J. M. (2022) · Hepatology Communications · doi:10.1002/hep4.2035 · Cited by 14
Metadata
- Authors
- Noureddin, M., & Sanyal, A. J.
- Venue
- Current Hepatology Reports
- Published
- 2018-10-31
- Volume
- 17
- Issue
- 4
- Pages
- 350-360
- ISSN
- 1540-3416 (ISSN-L)
- 2195-9595
- OpenAlex
- W2898705711
- Cited by
- 134
- References
- 37
- FWCI
- 7.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pathogenesis of NASH: the Impact of Multiple Pathways. https://app.cochat.ai/papers/10.1007/s11901-018-0425-7
- The paper
- Noureddin, M., & Sanyal, A. J. (2018). Pathogenesis of NASH: the Impact of Multiple Pathways. Current Hepatology Reports. https://doi.org/10.1007/s11901-018-0425-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.